Friday, May 1, 2026

Bank of Korea Flags U.S. Tariff and Policy Uncertainty: Can South Korea’s KOSPI Stay Firm After Crossing 5,900?

The Bank of Korea warns of volatility in stock markets due to U.S. tariffs but remains optimistic about economic recovery driven by semiconductors.

Exploring North Korea’s Healthcare Revolution: The Role of the New Pyongyang General Hospital in 2026

North Korea appointed Jeong Geum-cheol as director of the Pyongyang General Hospital, emphasizing public welfare and healthcare expansion.

Cosmecca Selected for Government Robotics Program, Moves to Build AI-Driven Autonomous Manufacturing

Cosmecca is set to build an AI-based autonomous manufacturing system to enhance efficiency and safety in its packaging processes.

Tag: ABL Bio

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

ABL209: The Promising Dual Antibody ADC Revolutionizing Cancer Treatment in 2026

ABL Bio's ABL209 shows promising anti-cancer effects with broad safety in preclinical studies, advancing to Phase 1 trials in the U.S.

FDA Grants Orphan Drug Status to Tovecimig: What This Means for Cholangiocarcinoma Treatment

ABL Bio's Tovecimig receives Orphan Drug Designation from the FDA, enhancing its approval prospects for cholangiocarcinoma treatment.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Unlocking Cancer Treatment: ABL206 and ABL209’s Promising Non-Clinical Data Revealed at AACR

ABL Bio will present preclinical data for its ADCs ABL206 and ABL209 at AACR 2023, showcasing promising anti-cancer efficacy.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

How ABL Bio’s Grabody-B Revolutionizes siRNA Delivery: A Game-Changer for Brain Disease Treatment?

ABL Bio's Grabody-B technology effectively delivers siRNA across the blood-brain barrier, enhancing treatment for brain and systemic diseases.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.